ECG AI-Guided Screening for Low Ejection Fraction

Mayo Clinic358 enrolled

Overview

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

358

Conditions

Asymptomatic Left Ventricular Systolic Dysfunction (Disorder)Heart Failure

Interventions

AI-enabled ECG-based Screening ToolOTHER

A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primary care clinicians who are part of a participating care team that care for adult patients and have the ability to order ECG and TTE (this includes physicians, nurse practitioners, and physician assistants). Exclusion Criteria: * Primary care clinicians working in pediatrics, acute care, nursing homes, and resident care teams.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

New Diagnosis of Low Ejection Fraction (defined as ejection fraction ≤50%)

Ejection fraction obtained by echocardiography.

Time frame: Within 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.